ABVC BioPharma (NASDAQ:ABVC) Trading 11.3% Higher – What’s Next?

Posted by Doug Wharley on Apr 3rd, 2026

ABVC BioPharma, Inc. (NASDAQ:ABVC – Get Free Report)’s share price traded up 11.3% during trading on Wednesday . The stock traded as high as $1.13 and last traded at $1.08. 141,320 shares were traded during mid-day trading, an increase of 170% from the average session volume of 52,307 shares. The stock had previously closed at $0.9701.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of ABVC BioPharma in a research report on Monday, December 29th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, ABVC BioPharma presently has a consensus rating of “Sell”.

Check Out Our Latest Analysis on ABVC

ABVC BioPharma Stock Performance

The stock has a market capitalization of $27.73 million, a price-to-earnings ratio of -2.73 and a beta of 0.38. The firm’s fifty day moving average price is $1.49 and its 200 day moving average price is $2.23.

ABVC BioPharma (NASDAQ:ABVC – Get Free Report) last announced its earnings results on Tuesday, March 3rd. The company reported ($0.11) earnings per share (EPS) for the quarter.

Hedge Funds Weigh In On ABVC BioPharma

Hedge funds have recently bought and sold shares of the company. Millennium Management LLC purchased a new position in ABVC BioPharma during the 3rd quarter valued at about $60,000. Citadel Advisors LLC acquired a new stake in shares of ABVC BioPharma during the third quarter worth about $48,000. Finally, Geode Capital Management LLC boosted its stake in shares of ABVC BioPharma by 7.7% in the fourth quarter. Geode Capital Management LLC now owns 202,365 shares of the company’s stock valued at $431,000 after purchasing an additional 14,553 shares during the period. Institutional investors and hedge funds own 11.38% of the company’s stock.

ABVC BioPharma Company Profile

(Get Free Report)

ABVC BioPharma is a clinical-stage biotechnology company focused on the discovery and development of novel vaccine and immunotherapy candidates for oncology and infectious diseases. The company leverages a proprietary peptide-based platform to identify and synthesize immunogenic epitopes, aiming to stimulate targeted immune responses against tumor-associated and pathogen-derived antigens.

The company’s pipeline includes active immunotherapy programs designed to address a range of cancer indications, along with vaccine candidates targeting bacterial pathogens.